ASND Ascendis Pharma A/S

On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares. That is a striking move from a company that lost money in the second quarter of 2025. Here is what stands behind the announcement, and what the fine print does and does […]

Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform. Management highlighted once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. The regained TransCon metabolic and cardiovascular rights and plans for...

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO). The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 […]

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

Ascendis Pharma (ASND) share selloff on Tuesday after the termination of its collaboration agreement

Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S

Healthcare stocks were edging down Tuesday afternoon, with the NYSE Healthcare Index fractionally lo

Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD

Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis’s achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International […]

Ascendis Pharma A/S (NASDAQ:ASND) on Wednesday announced Week 52 data from the open-label sentinel cohort of its reACHin trial. The data showed that once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis alongside linear growth benefits in infants with achondroplasia aged 0 to under 2 years. Read Also: Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes Growth And Cranio-Cervical Health Treatment with TransCon CN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will receive royalties equal to 20% of U.S. Yuviwel net […]

Ascendis Pharma (NasdaqGS:ASND) drew fresh investor attention after Canada’s Drug Agency recommended conditional public reimbursement for Yorvipath, its parathyroid hormone replacement therapy for eligible adults with chronic hypoparathyroidism. Ascendis Pharma’s recent news flow, including the Canadian reimbursement recommendation for Yorvipath and the late August global settlement with BioMarin over Yuviwel, has arrived alongside strong price momentum, with a 90 day share price return of...

Ascendis Pharma (NasdaqGS:ASND) reached a global settlement and licensing agreement with BioMarin Pharmaceutical that resolves worldwide patent disputes related to Yuviwel. The deal grants Ascendis Pharma a license to continue commercializing Yuviwel and related products across global markets. Ascendis Pharma also received a positive reimbursement recommendation in Canada for Yorvipath for adults with chronic hypoparathyroidism. These legal and reimbursement outcomes affect Ascendis Pharma's...

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

BioMarin and Ascendis settled a global patent dispute over the achondroplasia drug Yuviwel on Sunday.

European equities traded in the US as American depositary receipts opened the week slightly lower la

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel. Ascendis Pharma’s Yuviwel (navepegritide, developed as TransCon CNP) is a once-weekly prescription injection approved by the FDA to increase linear height growth in children aged 2 years and older with achondroplasia who have open growth plates. In March, the FDA approved Yuviwel, the first and only once-w

First Solar upgraded, Celsius downgraded: Wall Street's top analyst calls

On August 13, Ascendis Pharma (NASDAQ:ASND) reported second-quarter results that showed how far its rare disease portfolio has come. Total product revenue roughly doubled from a year earlier to €315 million, and for the first time all three of the company’s approved TransCon therapies, SKYTROFA, YORVIPATH and YUVIWEL, were contributing meaningful sales in the same […]

Revenue surged 105% year-over-year as three approved products scale globally.

Ascendis Pharma stock has delivered a 5.8% gain year to date, yet current valuation checks and market pricing point to a company that is not clearly cheap at today’s levels. With recent positive clinical updates and index inclusion in the background, the key issue for investors is how much of that optimism is already embedded in the share price. Year to date, Ascendis Pharma is up 5.8%, which suggests recent news and progress are being recognized but not in a runaway rally. Progress across...

Ascendis Pharma earnings and trial updates set the stage Ascendis Pharma (NasdaqGS:ASND) caught investor attention after reporting second quarter 2026 results on August 13, alongside fresh clinical updates on its TransCon CNP programs in growth disorders. The company reported second quarter sales of €339.29 million, with net income of €206.97 million and basic earnings per share from continuing operations of €3.22, based on its latest earnings release. See our latest analysis for Ascendis...

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of

Ascendis Pharma AS (ASND) reports record Q2 2026 results with product revenue more than doubling year-over-year, driven by strong YORVIPATH and YUVIWEL performance.

European equities traded in the US as American depositary receipts were higher late Thursday morning

Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based therapies continued to increase. Chief Financial Officer Scott Smith said product revenue more than double

European equities traded in the US as American depositary receipts were heading higher late Thursday

European equities traded in the US as American depositary receipts rose late Tuesday morning with th

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The fund reported strong absolute returns and modestly outperformed the Russell 2000® Growth Index, which gained 25.7%. Global equities rebounded as resilient US growth, moderating inflation, strong earnings and […]

BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.

Ascendis Pharma reported new two-year radiographic outcomes from its pivotal ApproaCH trial of TransCon CNP (YUVIWEL) in children with achondroplasia. The data show continued improvements in lower limb alignment and maintained growth velocity over two years, with treatment generally well tolerated. This update follows recent US approval of TransCon CNP (YUVIWEL) and comes as the therapy remains under regulatory review in Europe. For investors watching Ascendis Pharma (NasdaqGS:ASND), the...

Ascendis Pharma stock has climbed 24.0% over the past month, yet the current valuation checks and market multiples point to a picture that is not clearly cheap or clearly expensive. The 24.0% gain over the past 30 days suggests investors have recently been willing to pay up for Ascendis Pharma, which raises the bar for what the fundamentals need to deliver next. Expectations around Ascendis Pharma's ability to turn its pipeline into sustained revenue growth can support the current share...